Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Defects in homologous recombination (HR) are found in some triple negative breast cancers, suggesting they may be sensitive to PARP inhibitors. In this phase II clinical trial of the PARP inhibitor rucaparib, changes in Ki67 levels did not correlate with markers of HR deficiency but HR deficiency wa...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-16142-7 |